Comparison of hypertension prevalence and the use of renin-angiotensin-aldosterone system blockers in hospitalized patients with COVID-19 and non-COVID-19 viral pneumonia
dc.contributor.author | Gormez, Selcuk | |
dc.contributor.author | Kirisoglu, Ceyda Erel | |
dc.contributor.author | Ekicibasi, Mehmet Erkan | |
dc.contributor.author | Degirmencioglu, Aleks | |
dc.contributor.author | Paudel, Ashok | |
dc.contributor.author | Akan, Gokce | |
dc.contributor.author | Atalar, Fatmahan | |
dc.contributor.author | Sariguzel, Nevin | |
dc.contributor.author | Pamukcu, Burak | |
dc.date.accessioned | 2023-02-21T12:38:13Z | |
dc.date.available | 2023-02-21T12:38:13Z | |
dc.date.issued | 2021-01-01 | |
dc.description.abstract | Objective: To compare the prevalence of hypertension and pre-existing use of renin-angiotensin-aldosterone system blockers in patients with coronavirus disease (COVID-19) and non-COVID-19 viral pneumonias. Methods: Real-time polymerase chain reaction confirmed COVID-19 and non-COVID-19 pneumonia patients were retrospectively analyzed. The presence of hypertension, coronary artery disease (CAD), and pre-existing use of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) were compared between the groups. Results: A total of 103 COVID-19 and 91 non-COVID-19 hospitalized viral pneumonia patients were enrolled. Hypertension and CAD were more common in patients with non-COVID-19 viral pneumonia than in patients with COVID-19 (39.6\% vs 22.3\%, respectively, p=0.012 and 24.2\% vs 4.9\%, respectively, p<0.001). In our study, 2.9\% and 6.8\% of patients with COVID-19 were on ACEIs and ARBs, respectively, whereas 13.2\% and 19.8\% of patients with non-COVID-19 viral pneumonia were on ACEIs and ARBs, respectively (p=0.009 and p=0.013). Neutrophil-to-lymphocyte ratio (p<0.001) was prominent in patients with non-COVID-19 viral pneumonia compared with patients with COVID-19. Conclusion: Our study results indicate that hypertension and CAD are more common among patients with non-COVID-19 viral pneumonia than patients with COVID-19. The prevalence of ACEIs and ARBs use was not higher in patients with COVID-19. Our results support that the use of ACEIs and ARBs do not play a specific role in patients with COVID-19. | |
dc.description.issue | 4 | |
dc.description.issue | JUN | |
dc.description.pages | 286+ | |
dc.description.volume | 49 | |
dc.identifier.doi | 10.5543/tkda.2021.87750 | |
dc.identifier.uri | https://hdl.handle.net/11443/2354 | |
dc.identifier.uri | http://dx.doi.org/10.5543/tkda.2021.87750 | |
dc.identifier.wos | WOS:000658329900007 | |
dc.publisher | AVES | |
dc.relation.ispartof | TURK KARDIYOLOJI DERNEGI ARSIVI-ARCHIVES OF THE TURKISH SOCIETY OF CARDIOLOGY | |
dc.subject | COVID-19 | |
dc.subject | viral pneumonia | |
dc.subject | hypertension | |
dc.subject | angiotensin-converting enzyme inhibitors | |
dc.subject | angiotensin II type 2 receptor blockers | |
dc.title | Comparison of hypertension prevalence and the use of renin-angiotensin-aldosterone system blockers in hospitalized patients with COVID-19 and non-COVID-19 viral pneumonia | |
dc.type | Article |
Files
Original bundle
1 - 1 of 1
- Name:
- TKDA-87750-ORIGINAL_ARTICLE-PAMUKCU.pdf
- Size:
- 1.37 MB
- Format:
- Adobe Portable Document Format